Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3911025 | 1.00 | MME (0.39) | MMEAURKARPS6KB1ROCK2ROCK1 | |
| SCHEMBL8255755 | 0.87 | MME (0.50) | MMENAALAD2 | |
| SCHEMBL5870135 | 0.87 | MME (0.50) | MMENAALAD2 | |
| SCHEMBL29448215 | 0.82 | MME (0.43) | MMENAALAD2FOLH1 | |
| SCHEMBL8249923 | 0.81 | MME (0.59) | MMEACE | |
| SCHEMBL5870219 | 0.81 | MME (0.59) | MMEACE | |
| SCHEMBL1159856 | 0.80 | CPB2 (0.35) | SLC7A5 | |
| SCHEMBL10826528 | 0.79 | MME (0.52) | MMEACE | |
| SCHEMBL466340 | 0.79 | GAA (0.40) | MMENAALAD2 | |
| SCHEMBL1643961 | 0.79 | GAA (0.40) | MMENAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | MME 1178/4885AURKA 1850/4885RPS6KB1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.